Literature

Patient selection for Drug-Eluting Bead irinotecan (DEBIRI) - the surgical oncologist's perspective

Date 28 September 2011
Where presented Asian Pacific HPBA 2011, Melbourne
Author(s) Dr Robert Martin
Resources

Download file

Feasibility of neoadjuvant Drug-Eluting Bead irinotecan (DEBIRI) for resectable colorectal liver metastases

Date 15 September 2011
Where presented AUGIS 2011, Belfast
Author(s) Mr Stephen Fenwick
Resources

Download file

DEBIRI TACE: Patterns and Predictors of Response

Date 15 September 2011
Where presented AUGIS 2011, Belfast
Author(s) Mr Robert Jones
Resources

Download file

Final results of a prospective randomized trial assessing survival at 2 years of DEBIRI vs FOLFIRI in patients with hepatic metastases from colorectal cancer

Date 12 September 2011
Where presented CIRSE 2011, Munich
Author(s) Prof G Fiorentini
Resources

Download file

Neoadjuvant DEBIRI, Drug-Eluting Bead irinotecan. One year follow-up, pathology and biology of response (symposium presentation)

Where presented June 22-25, 2011, Barcelona
Conference World Congress on Gastrointestinal Cancer (WCGIC)
Author(s) G Poston
Resources

Download file

Trans-arterial chemoembolisation of metastatic colorectal carcinoma to the liver using DEBIRI, Drug-Eluting Bead irinotecan, compared to FOLFIRI. Evaluation at two years of a phase III clinical trial (symposium presentation)

Where presented June 22-25, 2011, Barcelona
Conference World Congress on Gastrointestinal Cancer (WCGIC)
Author(s) G Fiorentini
Resources

Download file

DEBIRI, Drug-Eluting Bead irinotecan, a novel device for the localised treatment of liver metastases. Design, rationale and clinical data (symposium presentation)

Where presented June 22-25, 2011, Barcelona
Conference World Congress on Gastrointestinal Cancer (WCGIC)
Author(s) S Pluntke
Resources

Download file

Trans-arterial Chemoembolization of Liver Metastases from Colorectal Carcinoma Adopting Drug Eluting-Beads Loaded with Irinotecan Compared to FOLFIRI: Results at two years of a phase III clinical trial (presentation synopsis)

Where presented June 9 - 12, 2011, New York
Conference World Conference on Interventional Oncology (WCIO)
Author(s) C Aliberti, T Massimo, G Fiorentini et al
Resources

Download file

DEBIRI on colorectal cancer liver metastasis: tips & tricks (workshop)

Where presented 27 - 30 April 2011, Paris, France
Conference Global Embolization Symposium and Technologies
Author(s) I Marri & C Aliberti
Resources

Download file

DC Bead M1: preliminary results (workshop)

Where presented 27 - 30 April 2011, Paris, France
Conference Global Embolization Symposium and Technologies (GEST)
Author(s) P Huppert
Resources

Download file

Lessons learned from more than 600 Polyvinil-alcohol microspheres (PAM) DEBIRI treatments in a single institution: The oncologist perspective

Date 2 October - 5 October 2010, Valencia Spain
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Author(s) Prof G Fiorentini
Resources

Download file

DC Bead managing metastatic disease: Clinical rationale and pilot data

Date 2 October - 5 October 2010, Valencia Spain
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Author(s) Dr R Martin
Resources

Download file

DC Bead managing metastatic colorectal cancer: Clinical experience from Germany

Date 2 October - 5 October 2010, Valencia Spain
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Author(s) Prof P Huppert
Resources

Download file

Neoadjuvant Drug-Eluting Bead irinotecan (DEBIRI) for resectable colorectal liver metastases

Date 15 September - 17 September 2010, Bordeaux France
Where presented The European Society of Surgical Oncology (ESSO)
Author(s) Mr Graeme Poston
Resources

Download file

Drug-Eluting Bead Irinotecan (DEBIRI) Therapy of Liver Metastases from Colon Cancer with Concomitant FOLFOX 6 and Anti-Angiogenic Therapy

Date 30 June - 3 July 2010, Barcelona Spain
Where presented World Congress on Gastrointestinal Cancer (WCGIC)
Author(s) Dr Robert Martin
Resources

Download file

Drug-Eluting Bead Irinotecan (DEBIRI) Therapy in Combination with Anti-EGFR Treatment in Patients with Refractory Colorectal Cancer and Predominant Liver Metastases

Date 30 June - 3 July 2010, Barcelona Spain
Where presented World Congress on Gastrointestinal Cancer (WCGIC)
Author(s) Dr Dirk Arnold
Resources

Download file

Feasibility of Neoadjuvant Drug-Eluting Bead Irinotecan (DEBIRI) for Resectable Colorectal Liver Metastases

Date 30 June - 3 July 2010, Barcelona Spain
Where presented World Congress on Gastrointestinal Cancer (WCGIC)
Author(s) Mr Graeme Poston
Resources

Download file

Feasibility of neoadjuvant transarterial chemoembolization (TACE) using irinotecan beads (DEBIRI) before hepatectomy (HPX) for easily resectable colorectal liver metastases (RCLM): A phase II study

Date 4 - 8 June 2010, Chicago, USA
Where presented American Society of Clinical Oncology (ASCO) 2010
Author(s) G. J. Poston, E. O'Grady, H. Z. Malik et al
Resources

Download file

Trans Arterial Chemoembolization (TACE) using Irinotecan coated LC beads for treatment of Hepatic Metastases from Colorectal Cancer (CRC)

Date March 13 - 18 2010, Tampa, Florida
Where presented Society of Interventional Radiology (SIR) 2010
Author(s) G. Narayanan et al - (To establish the safety and efficacy of TACE with Irinotecan coated LC beads as a treatment modality for hepatic metastases from colorectal cancer)
Resources

Download file

TACE and intra-arterial chemotherapy

Date 19 – 23 September 2009, Lisbon Portugal
Where presented Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Author(s) J. Evans;Dept. of Radiology , Royal Liverpool University Hospital , Liverpool, United Kingdom.
Resources

Download file

Page 1 of 3 pages  1 2 3 > 

Regulatory Notices

Worldwide (excluding USA and Canada)

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead instructions for use.

USA

DC Bead is not currently available for sale or distribution in the USA. DC Bead has not been submitted for approval to the FDA.

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.